Arch Capital Group Ltd. Names Janice Englesbe Senior Vice President, Chief Risk Officer
Arch Capital Group Ltd. (“Arch”) today announced that Janice Englesbe will join the Company as Senior Vice President, Chief Risk Officer (CRO) effective February 25, 2019. Ms. Englesbe will be based in Arch’s Bermuda office and report to François Morin, the Company’s Executive Vice President and Chief Financial Officer.
As CRO, Ms. Englesbe will have overall responsibility for the Company’s risk management function. Additionally, she will help formulate and implement business strategies and provide comprehensive counsel to the executive leaders and board members.
“Janice brings a wealth of experience and demonstrated ability to implement practical results,” Mr. Morin said. “I’m looking forward to the unique perspective and leadership she will bring to Arch.”
Ms. Englesbe has over 25 years of risk and finance experience, including Group Deputy Chief Risk Officer of General Re, and has been named one of Intelligent Insurer’s 100 Influential Women in Re/insurance. She holds a bachelor’s degree in economics from the University of Pennsylvania’s Wharton School of Business.
Arch Capital Services
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
PA-TELEFLEX21.3.2019 12:32:08 CET | Pressemeddelelse
Teleflex Announces Real-World Data Demonstrating the Effectiveness of the UroLift® System to Treat Patients with Enlarged Prostate
CA-SMITHS-DETECTION21.3.2019 12:25:08 CET | Pressemeddelelse
Smiths Detection Now Has Two Scanners with ECAC Standard 3.1 Approval
APR21.3.2019 11:32:12 CET | Pressemeddelelse
Rare Diseases: PKU GOLIKE® Debuts in Germany
HOLOGIC21.3.2019 11:02:09 CET | Pressemeddelelse
Hologic Opens State-Of-The-Art Learning and Experience Centre In Zaventem, Belgium
SAMSUNG-BIOEPIS-CO-LTD21.3.2019 10:04:05 CET | Pressemeddelelse
Samsung Bioepis Announces Three-year Follow-up Data for Biosimilar ONTRUZANT® (trastuzumab) in Early or Locally Advanced HER2-positive Breast Cancer
CA-TRADESHIFT21.3.2019 09:02:07 CET | Pressemeddelelse
Tradeshift partnership with FRDM wins Treasury4Good Award for Best CSR/ESG Technology Solution
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum